{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T04:59:30Z","timestamp":1781326770998,"version":"3.54.1"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ejphar.2025.177937","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T08:38:18Z","timestamp":1752568698000},"page":"177937","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Mechanisms and clinical perspectives on imeglimin for insulin resistance in obese patients"],"prefix":"10.1016","volume":"1003","author":[{"given":"Tingzhou","family":"Hou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3820-0725","authenticated-orcid":false,"given":"Wenwen","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2025.177937_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2021.102323","article-title":"Efficacy and safety of imeglimin in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized clinical trials","volume":"15","author":"Abdelhaleem","year":"2021","journal-title":"Diabetes Metabol. Syndr."},{"key":"10.1016\/j.ejphar.2025.177937_bib2","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.bbrc.2006.05.042","article-title":"Regulation of intracellular levels of NAD: a novel role for CD38","volume":"345","author":"Aksoy","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2025.177937_bib3","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2337\/db09-0942","article-title":"Adipocyte turnover: relevance to human adipose tissue morphology","volume":"59","author":"Arner","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2025.177937_bib4","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.vph.2012.05.003","article-title":"From excess adiposity to insulin resistance: the role of free fatty acids","volume":"57","author":"Capurso","year":"2012","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177937_bib5","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1142\/S0192415X21500695","article-title":"14-Deoxy-11,12-Didehydroandrographolide ameliorates glucose intolerance enhancing the LKB1\/AMPK[Formula: see text]\/TBC1D1\/GLUT4 signaling pathway and inducing GLUT4 expression in myotubes and skeletal muscle of Obese mice","volume":"49","author":"Chen","year":"2021","journal-title":"Am. J. Chin. Med."},{"key":"10.1016\/j.ejphar.2025.177937_bib6","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1124\/dmd.120.000154","article-title":"In vitro investigation, pharmacokinetics, and disposition of imeglimin, a novel oral antidiabetic drug, in preclinical species and humans","volume":"48","author":"Cl\u00e9mence","year":"2020","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejphar.2025.177937_bib7","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.2337\/db21-0587","article-title":"Contraction-mediated glucose transport in skeletal muscle is regulated by a framework of AMPK, TBC1D1\/4, and Rac1","volume":"70","author":"de Wendt","year":"2021","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2025.177937_bib8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.metabol.2015.10.014","article-title":"Metformin-associated lactic acidosis: current perspectives on causes and risk","volume":"65","author":"DeFronzo","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.ejphar.2025.177937_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/biom9120850","article-title":"Modulatory mechanisms of the NLRP3 inflammasomes in diabetes","volume":"9","author":"Ding","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejphar.2025.177937_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118868","article-title":"Aerobic training improves NAFLD markers and insulin resistance through AMPK-PPAR-\u03b1 signaling in Obese mice","volume":"266","author":"Diniz","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2025.177937_bib11","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s10863-018-9767-7","article-title":"Mitochondrial NADH redox potential impacts the reactive oxygen species production of reverse Electron transfer through complex I","volume":"50","author":"Dubouchaud","year":"2018","journal-title":"J. Bioenerg. Biomembr."},{"key":"10.1016\/j.ejphar.2025.177937_bib12","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/dom.14613","article-title":"Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): a 52-week, open-label, multicentre phase 3 trial","volume":"24","author":"Dubourg","year":"2022","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejphar.2025.177937_bib13","doi-asserted-by":"crossref","first-page":"952","DOI":"10.2337\/dc20-0763","article-title":"Efficacy and safety of imeglimin monotherapy versus placebo in Japanese patients with type 2 diabetes (TIMES 1): a double-blind, randomized, placebo-controlled, parallel-group, multicenter phase 3 trial","volume":"44","author":"Dubourg","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2025.177937_bib14","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s00228-020-02929-6","article-title":"Absence of QTc prolongation in a thorough QT study with imeglimin, a first in class oral agent for type 2 diabetes mellitus","volume":"76","author":"Dubourg","year":"2020","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177937_bib15","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/dom.14285","article-title":"Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled, dose-ranging phase 2b trial","volume":"23","author":"Dubourg","year":"2021","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejphar.2025.177937_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1010825","article-title":"Preservation effect of imeglimin on pancreatic \u03b2-cell mass: noninvasive evaluation using (111)In-exendin-4 SPECT\/CT imaging and the perspective of mitochondrial involvements","volume":"13","author":"Fauzi","year":"2022","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ejphar.2025.177937_bib17","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/jdi.13951","article-title":"Current understanding of imeglimin action on pancreatic \u03b2-cells: involvement of mitochondria and endoplasmic reticulum homeostasis","volume":"14","author":"Fauzi","year":"2023","journal-title":"J. Diabetes Investig."},{"key":"10.1016\/j.ejphar.2025.177937_bib18","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1210\/edrv.19.4.0336","article-title":"Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects","volume":"19","author":"Ferrannini","year":"1998","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.ejphar.2025.177937_bib19","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.2337\/dc13-2349","article-title":"The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy","volume":"37","author":"Fouqueray","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2025.177937_bib20","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2337\/dc12-0453","article-title":"The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy","volume":"36","author":"Fouqueray","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2025.177937_bib21","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.molcel.2008.03.003","article-title":"AMPK phosphorylation of raptor mediates a metabolic checkpoint","volume":"30","author":"Gwinn","year":"2008","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejphar.2025.177937_bib22","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/jdi.14247","article-title":"Factors contributing to the clinical effectiveness of imeglimin monotherapy in Japanese patients with type 2 diabetes mellitus","volume":"15","author":"Hagi","year":"2024","journal-title":"J. Diabetes Investig."},{"key":"10.1016\/j.ejphar.2025.177937_bib23","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/jdi.14070","article-title":"Efficacy, safety and tolerability of imeglimin in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials","volume":"14","author":"Hagi","year":"2023","journal-title":"J. Diabetes Investig."},{"key":"10.1016\/j.ejphar.2025.177937_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0241651","article-title":"Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action","volume":"16","author":"Hallakou-Bozec","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2025.177937_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.193","article-title":"Imeglimin preserves islet \u03b2-cell mass in type 2 diabetic ZDF rats","volume":"4","author":"Hallakou-Bozec","year":"2021","journal-title":"Endocrinol Diabetes Metab."},{"key":"10.1016\/j.ejphar.2025.177937_bib26","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/s41598-023-27689-y","article-title":"Effects of imeglimin on mitochondrial function, AMPK activity, and gene expression in hepatocytes","volume":"13","author":"Hozumi","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2025.177937_bib27","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1111\/jdi.14085","article-title":"Imeglimin-mediated glycemic control in maternally inherited deafness and diabetes","volume":"14","author":"Ishibashi","year":"2023","journal-title":"J. Diabetes Investig."},{"key":"10.1016\/j.ejphar.2025.177937_bib28","doi-asserted-by":"crossref","first-page":"376","DOI":"10.2337\/dbi21-0035","article-title":"Imeglimin to the rescue: enhanced CHOP\/GADD34\/eIF2\u03b1 signaling axis promotes \u03b2-Cell survival","volume":"71","author":"Jo","year":"2022","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2025.177937_bib29","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1080\/14656566.2020.1729123","article-title":"Clinical pharmacology of imeglimin for the treatment of type 2 diabetes","volume":"21","author":"Johansson","year":"2020","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejphar.2025.177937_bib30","doi-asserted-by":"crossref","first-page":"30045","DOI":"10.1074\/jbc.270.50.30045","article-title":"Regulatory role of CD38 (ADP-Ribosyl cyclase\/cyclic ADP-ribose hydrolase) in insulin secretion by glucose in pancreatic beta cells. Enhanced insulin secretion in CD38-expressing transgenic mice","volume":"270","author":"Kato","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2025.177937_bib31","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.bbrc.2021.07.090","article-title":"Imeglimin prevents heart failure with preserved ejection fraction by recovering the impaired unfolded protein response in mice subjected to cardiometabolic stress","volume":"572","author":"Kitakata","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2025.177937_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.plipres.2019.101020","article-title":"A global perspective on the crosstalk between saturated fatty acids and toll-like receptor 4 in the etiology of inflammation and insulin resistance","volume":"77","author":"Li","year":"2020","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.ejphar.2025.177937_bib33","article-title":"Safety of sodium-glucose transporter 2 (SGLT-2) inhibitors in patients with type 2 diabetes: a meta-analysis of cohort studies","volume":"14","author":"Li","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177937_bib34","doi-asserted-by":"crossref","first-page":"424","DOI":"10.2337\/db21-0123","article-title":"Imeglimin ameliorates \u03b2-Cell apoptosis by modulating the endoplasmic reticulum homeostasis pathway","volume":"71","author":"Li","year":"2022","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2025.177937_bib35","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/nyas.12098","article-title":"Type 2 diabetes in east Asians: similarities and differences with populations in Europe and the United States","volume":"1281","author":"Ma","year":"2013","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejphar.2025.177937_bib36","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1440-1681.2006.04362.x","article-title":"Exercise and skeletal muscle glucose transporter 4 expression: molecular mechanisms","volume":"33","author":"McGee","year":"2006","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.ejphar.2025.177937_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.102005","article-title":"Reactive oxygen species in exercise and insulin resistance: working towards personalized antioxidant treatment","volume":"44","author":"McKeegan","year":"2021","journal-title":"Redox Biol."},{"key":"10.1016\/j.ejphar.2025.177937_bib38","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.21873\/invivo.13214","article-title":"Safety and efficacy of imeglimin for type 2 diabetes in patients undergoing dialysis","volume":"37","author":"Mima","year":"2023","journal-title":"In Vivo"},{"key":"10.1016\/j.ejphar.2025.177937_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20081386","article-title":"How mitochondria produce reactive oxygen species","volume":"417","author":"Murphy","year":"2009","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejphar.2025.177937_bib40","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jphs.2023.07.002","article-title":"Imeglimin prevents visceral hypersensitivity and colonic hyperpermeability in irritable bowel syndrome rat model","volume":"153","author":"Nozu","year":"2023","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2025.177937_bib41","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1146\/annurev-pathol-012513-104649","article-title":"The role of endoplasmic reticulum stress in human pathology","volume":"10","author":"Oakes","year":"2015","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.ejphar.2025.177937_bib42","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1007\/s13300-022-01298-w","article-title":"The effects of imeglimin on the daily glycemic profile evaluated by intermittently scanned continuous glucose monitoring: retrospective, single-center, observational study","volume":"13","author":"Oda","year":"2022","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.ejphar.2025.177937_bib43","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/dom.12452","article-title":"Imeglimin increases glucose-dependent insulin secretion and improves \u03b2-cell function in patients with type 2 diabetes","volume":"17","author":"Pacini","year":"2015","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejphar.2025.177937_bib44","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.lfs.2018.11.041","article-title":"Emerging role of unfolded protein response (UPR) mediated proteotoxic apoptosis in diabetes","volume":"216","author":"Pandey","year":"2019","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2025.177937_bib45","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/7489795","article-title":"Association of glycemic indices (hyperglycemia, glucose variability, and hypoglycemia) with oxidative stress and diabetic complications","author":"Papachristoforou","year":"2020","journal-title":"J. Diabetes Res."},{"key":"10.1016\/j.ejphar.2025.177937_bib46","doi-asserted-by":"crossref","first-page":"E461","DOI":"10.1152\/ajpendo.00009.2016","article-title":"Imeglimin lowers glucose primarily by amplifying glucose-stimulated insulin secretion in high-fat-fed rodents","volume":"311","author":"Perry","year":"2016","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2025.177937_bib47","first-page":"137","article-title":"Endoplasmic reticulum stress epigenetics is related to adiposity, dyslipidemia, and insulin resistance","volume":"7","author":"Ramos-Lopez","year":"2018","journal-title":"Adipocyte"},{"key":"10.1016\/j.ejphar.2025.177937_bib48","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/dom.14642","article-title":"Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): a randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period","volume":"24","author":"Reilhac","year":"2022","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejphar.2025.177937_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes Federation diabetes atlas, 9(th) edition","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.ejphar.2025.177937_bib50","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.tem.2015.05.007","article-title":"Targeting endoplasmic reticulum stress in insulin resistance","volume":"26","author":"Salvad\u00f3","year":"2015","journal-title":"Trends Endocrinol. Metabol."},{"key":"10.1016\/j.ejphar.2025.177937_bib51","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-17657-3","article-title":"Imeglimin exerts favorable effects on pancreatic \u03b2-cells by improving morphology in mitochondria and increasing the number of insulin granules","volume":"12","author":"Sanada","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2025.177937_bib52","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqaa017","article-title":"Mitochondrial dysfunction, insulin resistance, and potential genetic implications","volume":"161","author":"Sangwung","year":"2020","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejphar.2025.177937_bib53","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1517\/13543784.2016.1152260","article-title":"Investigational insulin secretagogues for type 2 diabetes","volume":"25","author":"Scheen","year":"2016","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejphar.2025.177937_bib54","doi-asserted-by":"crossref","first-page":"13740","DOI":"10.1074\/jbc.M210689200","article-title":"Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes","volume":"278","author":"Senn","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2025.177937_bib55","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.tem.2011.05.002","article-title":"Stressed out about obesity: Ire1\u03b1-xbp1 in metabolic disorders","volume":"22","author":"Sha","year":"2011","journal-title":"Trends Endocrinol. Metabol."},{"key":"10.1016\/j.ejphar.2025.177937_bib56","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1365-2796.1993.tb00761.x","article-title":"Diacylglycerol\/protein kinase C signalling: a mechanism for insulin resistance?","volume":"234","author":"Shmueli","year":"1993","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.ejphar.2025.177937_bib57","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1172\/JCI29069","article-title":"Inflammation and insulin resistance","volume":"116","author":"Shoelson","year":"2006","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejphar.2025.177937_bib58","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1111\/cts.13221","article-title":"Imeglimin population pharmacokinetics and dose adjustment predictions for renal impairment in Japanese and Western patients with type 2 diabetes","volume":"15","author":"Tomita","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.ejphar.2025.177937_bib59","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.2337\/db14-1220","article-title":"Imeglimin normalizes glucose tolerance and insulin sensitivity and improves mitochondrial function in liver of a high-fat, high-sucrose diet mice model","volume":"64","author":"Vial","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2025.177937_bib60","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.211","article-title":"The mechanism by which imeglimin inhibits gluconeogenesis in rat liver cells","volume":"4","author":"Vial","year":"2021","journal-title":"Endocrinol Diabetes Metab."},{"key":"10.1016\/j.ejphar.2025.177937_bib61","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s40268-015-0099-3","article-title":"Imeglimin: a potential new multi-target drug for type 2 diabetes","volume":"15","author":"Vuylsteke","year":"2015","journal-title":"Drugs R&D"},{"key":"10.1016\/j.ejphar.2025.177937_bib62","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.cmet.2015.06.007","article-title":"Targeted induction of ceramide degradation leads to improved systemic metabolism and reduced hepatic steatosis","volume":"22","author":"Xia","year":"2015","journal-title":"Cell Metab."},{"key":"10.1016\/j.ejphar.2025.177937_bib63","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.cell.2013.12.010","article-title":"Regulation of ferroptotic cancer cell death by GPX4","volume":"156","author":"Yang","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2025.177937_bib64","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8768954","article-title":"Molecular mechanisms by which imeglimin improves glucose homeostasis","volume":"2020","author":"Yaribeygi","year":"2020","journal-title":"J. Diabetes Res."},{"key":"10.1016\/j.ejphar.2025.177937_bib65","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/978-3-319-48382-5_12","article-title":"Insulin resistance, obesity and lipotoxicity","volume":"960","author":"Yaz\u0131c\u0131","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ejphar.2025.177937_bib66","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/ddr.21636","article-title":"A review of phenformin, metformin, and imeglimin","volume":"81","author":"Yendapally","year":"2020","journal-title":"Drug Dev. Res."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925006910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925006910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:36:52Z","timestamp":1762144612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299925006910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":66,"alternative-id":["S0014299925006910"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177937","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanisms and clinical perspectives on imeglimin for insulin resistance in obese patients","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177937","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"177937"}}